ArticleEmerging infectious diseases2021
Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Whole-Genome Sequencing of RSV and Phylogeographic Assessment of Viral Importations into Russia.Viruses · 2026Article
- Results From the Third and Fourth WHO External Quality Assessments for the Molecular Detection of Respiratory Syncytial Virus.Influenza and other respiratory viruses · 2026Article
- Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.The Journal of infectious diseases · 2026Article
- Prevalence and genetic diversity of respiratory syncytial viruses circulating in Bulgaria, 2023-2025.Frontiers in cellular and infection microbiology · 2026Article
- Determinants of respiratory syncytial virus and human metapneumovirus transmission.Clinical microbiology reviews · 2025Review
- Development and Validation of a New Set of Primers for Identification of Circulating Lineages and Palivizumab/Nirsevimab Resistance in HRSV Isolates from Cabo Verde.Tropical medicine and infectious disease · 2025Article
- Epidemiology and genetic diversity of human respiratory syncytial virus in Belgium between 2011 and 2019.Virology journal · 2024Article
- Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level.Emerging infectious diseases · 2024Article
- Microbiological and epidemiological features of respiratory syncytial virus.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Article
- Respiratory syncytial virus infection and novel interventions.Nature reviews. Microbiology · 2023Review
- Circulation patterns and molecular epidemiology of human respiratory syncytial virus over five consecutive seasons in Morocco.Influenza and other respiratory viruses · 2023Article
- The road to approved vaccines for respiratory syncytial virus.NPJ vaccines · 2023Review
- New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic.The European respiratory journal · 2023Article
- Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019-2020.Influenza and other respiratory viruses · 2023Article
- A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.Journal of medical virology · 2022Article
- No human respiratory syncytial virus but SARS-CoV-2 found in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran.Journal of medical virology · 2022Article
- Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level.Emerging infectious diseases · 2022Article
- Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Clinical and biological consequences of respiratory syncytial virus genetic diversity.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 1 institution in 1 country.
Funding
Abstract
Human respiratory syncytial virus (HRSV) is the leading viral cause of serious pediatric respiratory disease, and lifelong reinfections are common. Its 2 major subgroups, A and B, exhibit some antigenic variability, enabling HRSV to circulate annually. Globally, research has increased the number of HRSV genomic sequences available. To ensure accurate molecular epidemiology analyses, we propose a uniform nomenclature for HRSV-positive samples and isolates, and HRSV sequences, namely: HRSV/subgroup identifier/geographic identifier/unique sequence identifier/year of sampling. We also propose a template for submitting associated metadata. Universal nomenclature would help researchers retrieve and analyze sequence data to better understand the evolution of this virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.